Article information
Full text is only aviable in PDF
References
[1]
C Fletcher, R Peto.
The natural history of chronic airflow obstruction.
Br Med J, 1 (1977), pp. 1645-1648
[2]
M Orozco-Levi, J García-Aymerich, J Villar, A Ramírez-Sarmiento, JM Antó, J Gea.
Wood smoke exposure and risk of chronic obstructive pulmonary disease.
Eur Respir J, 27 (2006), pp. 542-546
[3]
Alpha-1-Antitrypsin Deficiency Registry Study Group.
Survival and FEV1 decline in individuals with severe deficiency of alpha-1-antitrypsin.
Am J Respir Crit Care Med, 158 (1998), pp. 49-59
[4]
V Sobradillo, M Miravitlles, CA Jiménez, R Gabriel, JL Viejo, JF Masa, et al.
Estudio epidemiológico de la EPOC en España (IBERPOC): prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo.
Arch Bronconeumol, 35 (1999), pp. 159-166
[5]
AM Menezes, R Pérez-Padilla, JR Jardim, A Muino, MV López, G Valdivia, et al.
Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study.
Lancet, 366 (2005), pp. 1875-1881
[6]
F García-Río, JM Pino, A Dorgham, A Alonso, J Villamor.
Spirometric reference equations for European females and males aged 65-85 yrs.
Eur Respir J, 24 (2004), pp. 397-405
[7]
S Kesten, KR Chapman.
Physician perceptions and management of COPD.
Chest, 104 (1993), pp. 254-258
[8]
AM Schols, J Slangen, L Volovics, EF Wouters.
Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 157 (1998), pp. 1791-1797
[9]
A Casas, J Vilaró, R Rabinovich, A Mayer, JA Barberá, R Rodríguez-Roisin, et al.
Encouraged 6-min walking test indicates maximum sustainable exercise in COPD patients.
Chest, 128 (2005), pp. 55-61
[10]
BR Celli, CG Cote, JM Marín, C Casanova, M Montes de Oca, RA Méndez, et al.
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.
N Engl J Med, 350 (2004), pp. 1005-1012
[11]
C Silagy, T Lancaster, L Stead, D Mant, G Fowler.
Nicotine replacement therapy for smoking cessation.
Cochrane Database Syst Rev, (2004), pp. CD000146
[12]
DE Jorenby, SJ Leischow, MA Nides, SI Rennard, JA Johnston, AR Hughes, et al.
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
N Engl J Med, 340 (1999), pp. 685-691
[13]
K Cahill, L Stead, T Lancaster.
Nicotine receptor partial agonists for smoking cessation.
Cochrane Database Syst Rev, (2007), pp. CD006103
[14]
CA Jiménez-Ruiz, S Solano Reina, JM González de Vega, MJ Ruiz Pardo, S Flórez Perona, A Ramos Pinedo, et al.
Normativa para el tratamiento del tabaquismo.
Arch Bronconeumol, 35 (1999), pp. 499-506
[15]
KL Nichol, L Baken, A Nelson.
Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.
Ann Intern Med, 130 (1999), pp. 397-403
[16]
I Alfageme, R Vázquez, N Reyes, J Muñoz, A Fernández, M Hernández, et al.
Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.
Thorax, 61 (2006), pp. 189-195
[17]
P Calverley.
Breathlessness during exercise in COPD: how do the drugs work?.
Thorax, 59 (2004), pp. 455-457
[18]
COMBIVENT Inhalation Aerosol Study Group.
In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial.
Chest, 105 (1994), pp. 1411-1419
[19]
G Boyd, AH Morice, JC Pounsford, M Siebert, N Peslis, C Crawford.
An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD).
Eur Respir J, 10 (1997), pp. 815-821
[20]
R Aalbers, J Ayres, V Backer, M Decramer, PA Lier, P Magyar, et al.
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.
Eur Respir J, 19 (2002), pp. 936-943
[21]
DE O'Donnell, T Fluge, F Gerken, A Hamilton, K Webb, B Aguilaniu, et al.
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.
Eur Respir J, 23 (2004), pp. 832-840
[22]
JA van Noord, JL Aumann, E Janssens, JJ Smeets, J Verhaert, B Disse, et al.
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
Eur Respir J, 26 (2005), pp. 214-222
[23]
FS Ram, PW Jones, AA Castro, JA de Brito, AN Atallah, Y Lacasse, et al.
Oral theophylline for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2002), pp. CD003902
[24]
RA Pauwels, CG Lofdahl, LA Laitinen, JP Schouten, DS Postma, NB Pride, et al.
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.
N Engl J Med, 340 (1999), pp. 1948-1953
[25]
PS Burge, PM Calverley, PW Jones, S Spencer, JA Anderson, TK Maslen.
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
BMJ, 320 (2000), pp. 1297-1303
[26]
DD Sin, JV Tu.
Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 164 (2001), pp. 580-584
[27]
PM Calverley, JA Anderson, B Celli, GT Ferguson, C Jenkins, PW Jones, et al.
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
N Engl J Med, 356 (2007), pp. 775-789
[28]
PS Burge, PM Calverley, PW Jones, S Spencer, JA Anderson.
Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.
Thorax, 58 (2003), pp. 654-658
[29]
P Calverley, R Pauwels, J Vestbo, P Jones, N Pride, A Gulsvik, et al.
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Lancet, 361 (2003), pp. 449-456
[30]
W Szafranski, A Cukier, A Ramírez, G Menga, R Sansores, S Nahabedian, et al.
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Eur Respir J, 21 (2003), pp. 74-81
[31]
PM Calverley, W Boonsawat, Z Cseke, N Zhong, S Peterson, H Olsson.
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.
Eur Respir J, 22 (2003), pp. 912-919
[32]
EF Wouters, DS Postma, B Fokkens, WC Hop, J Prins, AF Kuipers, et al.
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Thorax, 60 (2005), pp. 480-487
[33]
PJ Poole, PN Black.
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2006), pp. CD001287
[34]
M Decramer, MM Ruttenvan, PN Dekhuijzen, T Troosters, C van Herwaarden, R Pellegrion, et al.
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
Lancet, 365 (2005), pp. 1552-1560
[35]
KF Rabe, ED Bateman, D O'Donnell, S Witte, D Bredenbroker, TD Bethke.
Roflumilast an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
Lancet, 366 (2005), pp. 563-571
[36]
Medical Research Council Working Party.
Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema.
Lancet, 1 (1981), pp. 681-685
[37]
Nocturnal Oxygen Therapy Trial Group.
Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease.
Ann Intern Med, 93 (1980), pp. 391-398
[38]
D Gorecka, K Gorzelak, P Sliwinski, M Tobiasz, J Zielinski.
Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia.
Thorax, 52 (1997), pp. 674-679
[39]
J García-Aymerich, P Lange, M Benet, P Schnohr, JM Antó.
Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study.
Thorax, 61 (2006), pp. 772-778
[40]
Y Lacasse, E Wong, GH Guyatt, D King, DJ Cook, RS Goldstein.
Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease.
Lancet, 348 (1996), pp. 1115-1119
[41]
MT Hernández, TM Rubio, FO Ruiz, HS Riera, RS Gil, JC Gómez.
Results of a home-based training program for patients with COPD.
Chest, 118 (2000), pp. 106-114
[42]
L Puente-Maestu, ML Sanz, P Sanz, JM Ruiz de Ona, JL Rodríguez-Hermosa, BJ Whipp.
Effects of two types of training on pulmonary and cardiac responses to moderate exercise in patients with COPD.
Eur Respir J, 15 (2000), pp. 1026-1032
[43]
P De Lucas, R Guell, V Sobradillo, CA Jiménez, M Sangenís, T Montemayor, et al.
Rehabilitación respiratoria. Normativa SEPAR.
Arch Bronconeumol, 36 (2000), pp. 257-274
[44]
L Nici, C Donner, E Wouters, R Zuwallack, N Ambrosino, J Bourbeau, et al.
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation.
Am J Respir Crit Care Med, 173 (2006), pp. 1390-1413
[45]
C Casanova, BR Celli, L Tost, E Soriano, J Abreu, V Velasco, et al.
Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD.
Chest, 118 (2000), pp. 1582-1590
[46]
E Clini, C Sturani, A Rossi, S Viaggi, A Corrado, C Donner, et al.
The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients.
Eur Respir J, 20 (2002), pp. 529-538
[47]
AK Simonds.
Ethics and decision making in end stage lung disease.
Thorax, 58 (2003), pp. 272-277
[48]
R Rodríguez-Roisin.
Toward a consensus definition for COPD exacerbations.
Chest, 117 (2000), pp. 398-401
[49]
DS Postma.
When can an exacerbation of COPD be treated at home?.
Lancet, 351 (1998), pp. 1827-1828
[50]
E Pérez-Trallero, C García-de-la-Fuente, C García-Rey, F Baquero, L Aguilar, R Dal Ré, et al.
Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain.
Antimicrob Agents Chemother, 49 (2005), pp. 1965-1972
[51]
R Wood-Baker, EH Walters, P Gibson.
Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2001), pp. CD001288
[52]
FS Ram, JA Wedzicha, J Wright, M Greenstone.
Hospital at home for acute exacerbations of chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2003), pp. CD003573
[53]
E Sala, L Alegre, M Carrera, M Ibars, FJ Orriols, ML Blanco, et al.
Supported discharge shortens hospital stay in patients hospitalized because of an exacerbation of COPD.
Eur Respir J, 17 (2001), pp. 1138-1142
[54]
GH Murata, MS Gorby, TW Chick, AK Halperin.
Use of emergency medical services by patients with decompensated obstructive lung disease.
Ann Emerg Med, 18 (1989), pp. 501-506
[55]
JA Barberà, J Roca, A Ferrer, MA Félez, O Díaz, N Roger, et al.
Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease.
Eur Respir J, 10 (1997), pp. 1285-1291
[56]
AG Agustí, M Carrera, F Barbé, A Muñoz, B Togores.
Oxygen therapy during exacerbations of chronic obstructive pulmonary disease.
Eur Respir J, 14 (1999), pp. 934-939
[57]
L Brochard, J Mancebo, M Wysocki, F Lofaso, G Conti, A Rauss, et al.
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.
N Engl J Med, 333 (1995), pp. 817-822
[58]
PK Plant, JL Owen, MW Elliott.
Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial.
Lancet, 355 (2000), pp. 1931-1935
[59]
SM Studer, RD Levy, K McNeil, JB Orens.
Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness.
Eur Respir J, 24 (2004), pp. 674-685
[60]
JR Maurer, AE Frost, M Estenne, T Higenbottam, AR Glanville.
International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society.
Transplantation, 66 (1998), pp. 951-956
[61]
A Varela, KA Álvarez, A Roman, P Ussetti, F Zurbano.
Normativa sobre el estudio y seguimiento del receptor de un trasplante pulmonar.
Arch Bronconeumol, 37 (2001), pp. 307-315
[62]
A Fishman, F Martínez, K Naunheim, S Piantadosi, R Wise, A Ries, et al.
A randomized trial comparing lung-volume reduction surgery with medical therapy for severe emphysema.
N Engl J Med, 348 (2003), pp. 2059-2073
[63]
National Emphysema Treatment Trial Group.
Patients at high risk of death after lung volume-reduction surgery.
N Engl J Med, 345 (2001), pp. 1075-1083
[64]
IY Wan, TP Toma, DM Geddes, G Snell, T Williams, F Venuta, et al.
Bronchoscopic lung volume reduction for end-stage emphysema: report on the first 98 patients.
Chest, 129 (2006), pp. 518-526
[65]
EP Ingenito, RL Berger, AC Henderson, JJ Reilly, L Tsai, A Hoffman.
Bronchoscopic lung volume reduction using tissue engineering principles.
Am J Respir Crit Care Med, 167 (2003), pp. 771-778
[66]
GL Snider.
Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema.
Chest, 109 (1996), pp. 540-548
Copyright © 2008. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
